Evidence map›Paper›PMID 36510158›Full record

ArticleBMC pulmonary medicine2022

The predictive value of pulmonary function test before transplantation for chronic pulmonary graft-versus-host-disease after allogeneic hematopoietic stem cell transplantation.

Lingyi Yang, Jia Cheng, Fei Li, Ruiqi Qian, Xiuqin Zhang, Song Jin, Xuefeng He, Ting Xu, Xiaohui Hu, Xiao Ma and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Lingyi Yang *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Jia Cheng *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Fei Li *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Ruiqi QianDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Xiuqin ZhangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Song JinNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Xuefeng HeNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Ting XuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Xiaohui HuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Xiao MaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Jia ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Yehan ZhuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China. zhuyehan_sz@163.com.
Feng ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188, Shizi Street, Suzhou, 215006, Jiangsu Province, China. 13584861215@163.com.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CN

Funding

National Natural Science Foundation of China 81700173Science and Technology Program of Suzhou SKY2021039
6 · The paper itself

Abstract

backgroundPulmonary chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a devastating complication and often diagnosed at a late stage when lung dysfunction is irreversible. Identifying patients before transplant who are at risk may offer improved strategies to decrease the mortality. Bronchiolitis obliterans syndrome (BOS) is the typical manifestation of pulmonary cGVHD, which is clinically diagnosed by pulmonary function test (PFT). This study aimed to evaluate the predictive value of PFT pre-HSCT for BOS.

methodsA single center cohort of 923 allo-HSCT recipients was analyzed, including 15 patients who developed pulmonary cGVHD. Kaplan-Meier method was used to analyze the 3 year progression free survival and 3 year overall survival (OS). A Cox regression model was applied for univariate and multivariate models.

resultsThe 3 year cumulative incidence of pulmonary cGVHD was 2.04% (95% CI 1.00-3.08%). According to the cut-off values determined by receiver operator characteristic curve, higher ratio of forced expiratory volume during one second to forced vital capacity (FEV1/FVC) pre-HSCT was correlated to a lower incidence of pulmonary cGVHD [0.91% (95% CI 0.01-1.81%) vs. 3.61% (95% CI 1.30-5.92%), P < 0.01], and so as peak expiratory flow to predictive value (PEF/pred) [0.72% (95% CI 0-1.54%) vs. 3.74% (95% CI 1.47-6.01%), P < 0.01]. Multivariate analysis showed that FEV1/FVC (HR = 3.383, P = 0.047) and PEF/pred (HR = 4.426, P = 0.027) were independent risk factors for onset of BOS. Higher FEV1/FVC and PEF/pred level were related to a significantly decreased 3 year non-relapse mortality. The 3 year OS was superior in patients with higher PEF/pred [78.17% (95% CI 74.50-81.84%) vs. 71.14% (95% CI 66.08-76.20%), P = 0.01], while FEV1/FVC did not show significance difference.

conclusionOur results suggested that PFT parameters such as PEF/pred and FEV1/FVC could be predictors for pulmonary cGVHD and even transplant outcomes before HSCT.

Indexed as

Hematopoietic Stem Cell TransplantationForced Expiratory VolumeHumansLungRespiratory Function TestsRetrospective StudiesVital CapacityAllogeneic hematopoietic stem cell transplantationBronchiolitis obliterans syndromePeak expiratory flowPulmonary chronic graft-versus-host diseasePulmonary function testThe ratio of forced expiratory volume during one second to forced vital capacity

Identifiers

PMID36510158
PMCPMC9746214
OpenAlexW4311244906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.